NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

$4.80
-0.31 (-6.07%)
(As of 04/22/2024 ET)
Today's Range
$4.79
$5.12
50-Day Range
$3.75
$5.24
52-Week Range
$3.30
$7.00
Volume
2.11 million shs
Average Volume
5.14 million shs
Market Capitalization
$276.19 million
P/E Ratio
96.02
Dividend Yield
N/A
Price Target
N/A

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.34mentions of Vanda Pharmaceuticals in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.06) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

302nd out of 909 stocks

Pharmaceutical Preparations Industry

130th out of 420 stocks

VNDA stock logo

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Stock Price History

VNDA Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
Vanda Pharma Rejects Future Pak's Takeover Proposals; Stock Climbs
3 Biotech Stocks to Watch for Lucrative Gains
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
4/22/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
203
Year Founded
2002

Profitability

Net Income
$2.51 million
Pretax Margin
3.29%

Debt

Sales & Book Value

Annual Sales
$192.64 million
Book Value
$9.47 per share

Miscellaneous

Free Float
53,107,000
Market Cap
$276.19 million
Optionable
Optionable
Beta
0.76

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed in 2024?

Vanda Pharmaceuticals' stock was trading at $4.22 at the beginning of the year. Since then, VNDA shares have increased by 13.7% and is now trading at $4.80.
View the best growth stocks for 2024 here
.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decline of 17.0% from the March 15th total of 3,000,000 shares. Based on an average daily trading volume, of 1,860,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 4.6% of the company's shares are short sold.
View Vanda Pharmaceuticals' Short Interest
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, February, 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. The biopharmaceutical company had revenue of $45.27 million for the quarter, compared to analysts' expectations of $37 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 0.46% and a net margin of 1.30%.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX).iShares Neuroscience and Healthcare ETF (IBRN).

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.75%), Profit Investment Management LLC (0.38%) and Allspring Global Investments Holdings LLC (0.28%). Insiders that own company stock include Aranthan Jones II, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VNDA) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners